ABSCI CORPORATION - COMMON STOCK

Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD

11 Sep 2025 05:00:00 By Nasdaq GlobeNewswire

Absci Expands ABS-201 Scientific Advisory Board with Addition of Leading Dermatology Experts Dr. Rodney Sinclair and Dr. David Goldberg

25 Aug 2025 13:05:00 By Nasdaq GlobeNewswire

Absci to Participate in Upcoming Investor Conferences

20 Aug 2025 05:00:00 By Nasdaq GlobeNewswire

Absci Reports Business Updates and Second Quarter 2025 Financial and Operating Results

12 Aug 2025 13:05:01 By Nasdaq GlobeNewswire

Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target

06 Aug 2025 23:00:00 By Nasdaq GlobeNewswire

Absci to Report Business Updates and Second Quarter 2025 Financial and Operating Results on August 12, 2025

30 Jul 2025 13:05:00 By Nasdaq GlobeNewswire

Absci Announces Pricing of Public Offering of Common Stock

24 Jul 2025 17:45:17 By Nasdaq GlobeNewswire

Absci Announces Proposed Public Offering of Common Stock

24 Jul 2025 13:54:49 By Nasdaq GlobeNewswire

Absci Appoints Biopharma Leader Mary Szela to Board of Directors

07 Jul 2025 05:00:00 By Nasdaq GlobeNewswire

Absci to Participate in Upcoming Investor Conferences

20 May 2025 05:00:00 By Nasdaq GlobeNewswire

Absci Reports Business Updates and First Quarter 2025 Financial and Operating Results

13 May 2025 13:05:00 By Nasdaq GlobeNewswire

Absci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential Best-In-Class anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease

13 May 2025 13:01:00 By Nasdaq GlobeNewswire

Absci to Report Business Updates and First Quarter 2025 Financial and Operating Results on May 13, 2025

14 Apr 2025 13:05:00 By Nasdaq GlobeNewswire

Absci to Participate in Upcoming Investor Conferences

26 Mar 2025 05:00:01 By Nasdaq GlobeNewswire

Absci Reports Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results

18 Mar 2025 13:05:00 By Nasdaq GlobeNewswire

Absci to Report Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results on March 18, 2025

04 Mar 2025 13:05:00 By Nasdaq GlobeNewswire

Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

04 Mar 2025 13:00:00 By Nasdaq GlobeNewswire

Absci to Participate in the KeyBanc Capital Markets Healthcare Forum

04 Mar 2025 05:00:00 By Nasdaq GlobeNewswire

Absci to Participate in the TD Cowen 45th Annual Health Care Conference

18 Feb 2025 05:00:00 By Nasdaq GlobeNewswire

Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference

22 Jan 2025 05:00:00 By Nasdaq GlobeNewswire